• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics COVID-19 Classics

The COVE trial: mRNA-1273 vaccine for preventing COVID-19 [Classics Series]

byDeepti Shroff Karhade
July 15, 2022
in COVID-19 Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. In this phase 3 trial, the mRNA-1273 vaccine was found to be efficacious in preventing symptomatic infection from coronavirus disease 2019 (COVID-19) in comparison to a placebo control.

2. All serious cases of COVID-19 occurred in the placebo group and no major safety concerns were identified for the mRNA-1273 vaccine.

Original Date of Publication: February 2021

Study Rundown: The Coronavirus Efficacy (COVE) trial evaluated the efficacy of the mRNA-1273 at preventing symptomatic COVID-19 infection as compared to a placebo injection. The placebo group had significantly higher rates of COVID-19 infection at 14-day follow-up, which was consistent in subgroup analysis of participants with a previous COVID-19 infection and those aged 65 years or older. No cases of severe COVID-19 infection were seen in the intervention group and the incidence of serious adverse events did not differ significantly between groups. The primary limitation of the COVE trial was the short follow-up time for measuring efficacy and adverse events. Although, a two-year follow-up duration is planned for enrolled patients. The COVE trial was the first to demonstrate that the mRNA-1273 vaccine washighly efficacious at preventing COVID-19 infection with a low-risk safety profile for serious adverse events.

Click to read the study in NEJM

RELATED REPORTS

Fecal microbiota transplantation may be more effective than vancomycin in treating primary C. difficile infection

Poor communication closely associated with patient safety incidents

#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary

In-Depth [randomized control trial]: The participants of the COVE trial received two doses of either the mRNA-1273 vaccine (n = 15 210) or a placebo control injection (n = 15 210) with 28 days between doses and a 14-day follow-up time. The mRNA-1273 vaccine had 95.2% efficacy (95%CI 91.2-97.4) at preventing symptomatic COVID-19 infection as compared to placebo control. Notably, the mRNA-1273 vaccine was found to be 100% efficacious at preventing severe COVID-19 infection. Injection-site adverse events were higher in the mRNA-1273 group after both the first (84.2% versus 19.8%) and second injections (88.6% versus 18.8%). Similarly, systemic adverse reactions were also increased in the intervention group following the first (54.9% versus 42.2%) and second doses (79.4% versus 36.5%). Serious adverse event rates did not differ significantly between the mRNA-1273 and placebo injection groups.

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2021 Feb 4;384(5):403–16.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adverse eventsCoronavirusmRNA-1273 vaccinephase 3 trial
Previous Post

Incidence and predictors of multimorbidity in a Korean geriatric population

Next Post

The EMPACTA trial: Tocilizumab reduced COVID-19 disease-related adverse health outcomes [Classics Series]

RelatedReports

Antibiotic misconceptions persist in Medicaid-insured parents
Gastroenterology

Fecal microbiota transplantation may be more effective than vancomycin in treating primary C. difficile infection

June 16, 2025
Shared decision-making may be limited in PICU end-of-life discussions
Public Health

Poor communication closely associated with patient safety incidents

April 15, 2025
#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary
StudyGraphics

#VisualAbstract: Site-Specific Therapy Guided by a 90-Gene Expression Assay Improved Survival in Patients with Cancer of Unknown Primary

August 20, 2024
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Oncology

Dose-dense adjuvant therapy with epirubicin and cyclophosphamide effective for breast cancer

August 10, 2024
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The EMPACTA trial: Tocilizumab reduced COVID-19 disease-related adverse health outcomes [Classics Series]

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

10-second one-legged stance performance may predict survival in middle-aged and older individuals

#VisualAbstract: Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery

#VisualAbstract: Effect of Nitric Oxide via Cardiopulmonary Bypass on Ventilator-Free Days in Young Children Undergoing Congenital Heart Disease Surgery

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.